Pub Date : 2018-06-01DOI: 10.1142/S2575900018500064
Haibo Tan, Zhengwei Zhang, Wei-qi Bao, Y. Guan
Objective: To explore the method and quality control of [Formula: see text]C radiolabeled [Formula: see text]-SPD ([Formula: see text]-Stepholidine) and biodistribution of [Formula: see text]C-[Formula: see text]-SPD in vivo. Methods: (1) [Formula: see text]CO2 was produced by CTI RDS III cyclotron, converted [Formula: see text]CO2 to [Formula: see text]C–CH3I by CH3I die-block, and then converted it to [Formula: see text]C-Triflate–CH4, imported [Formula: see text]C-Triflate–CH4 to [Formula: see text]-SPD which was dissolved in Dimethyl sulfoxide [(CH3)2SO], reacted at common temperature and then obtained the product. (2) Take the sample of organs in different times 5, 15, 30, 60, 90[Formula: see text]min after injecting [Formula: see text]C-[Formula: see text]-SPD by vail in mice and measure the radioactive counts per minute (cpm), then the percent injection dose of wet tissue per gram (%ID/g) was calculated. Results: (1) The synthesis time of [Formula: see text]C-[Formula: see text]-SPD was 15 to 20[Formula: see text]min with chemical [Formula: see text]%, and PH values [Formula: see text], radiochemical [Formula: see text]% in 2[Formula: see text]h. All quality criteria of [Formula: see text]C-[Formula: see text]-SPD met the requirements of the positron radio-pharmaceuticals. (2) [Formula: see text]C-[Formula: see text]-SPD was of the characteristic that metabolism was through the liver, and kidney was the main excretory organ, which was [Formula: see text]%ID/g at 5[Formula: see text]min and was decreasing gradually, which was [Formula: see text][Formula: see text]ID/g in liver at 5[Formula: see text]min. Conclusion: (1) [Formula: see text]C-[Formula: see text]-SPD can be used to further study the animal or human. (2) [Formula: see text]C-[Formula: see text]-SPD could quickly discharge and decrease to the low level from background of issues in vivo.
{"title":"Preparation and preliminary biological evaluation of 11C-l-SPD","authors":"Haibo Tan, Zhengwei Zhang, Wei-qi Bao, Y. Guan","doi":"10.1142/S2575900018500064","DOIUrl":"https://doi.org/10.1142/S2575900018500064","url":null,"abstract":"Objective: To explore the method and quality control of [Formula: see text]C radiolabeled [Formula: see text]-SPD ([Formula: see text]-Stepholidine) and biodistribution of [Formula: see text]C-[Formula: see text]-SPD in vivo. Methods: (1) [Formula: see text]CO2 was produced by CTI RDS III cyclotron, converted [Formula: see text]CO2 to [Formula: see text]C–CH3I by CH3I die-block, and then converted it to [Formula: see text]C-Triflate–CH4, imported [Formula: see text]C-Triflate–CH4 to [Formula: see text]-SPD which was dissolved in Dimethyl sulfoxide [(CH3)2SO], reacted at common temperature and then obtained the product. (2) Take the sample of organs in different times 5, 15, 30, 60, 90[Formula: see text]min after injecting [Formula: see text]C-[Formula: see text]-SPD by vail in mice and measure the radioactive counts per minute (cpm), then the percent injection dose of wet tissue per gram (%ID/g) was calculated. Results: (1) The synthesis time of [Formula: see text]C-[Formula: see text]-SPD was 15 to 20[Formula: see text]min with chemical [Formula: see text]%, and PH values [Formula: see text], radiochemical [Formula: see text]% in 2[Formula: see text]h. All quality criteria of [Formula: see text]C-[Formula: see text]-SPD met the requirements of the positron radio-pharmaceuticals. (2) [Formula: see text]C-[Formula: see text]-SPD was of the characteristic that metabolism was through the liver, and kidney was the main excretory organ, which was [Formula: see text]%ID/g at 5[Formula: see text]min and was decreasing gradually, which was [Formula: see text][Formula: see text]ID/g in liver at 5[Formula: see text]min. Conclusion: (1) [Formula: see text]C-[Formula: see text]-SPD can be used to further study the animal or human. (2) [Formula: see text]C-[Formula: see text]-SPD could quickly discharge and decrease to the low level from background of issues in vivo.","PeriodicalId":23184,"journal":{"name":"Traditional Medicine and Modern Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S2575900018500064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43707678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To evaluate the curative effect of “Tertiary hospitals–Community Health Service Institutions–Family health care workers/patients to participate in the annular management of COPD” model in the treatment of chronic obstructive pulmonary disease (COPD). Methods: 516 patients with COPD in the stable period of the disease were invited to participate in this cluster randomized trial with 260 patients in the trial group, and the other 256 in the control group. All the patients were treated with the routine medicine regimen. The integrated intervention for the trial group includes educational activity, physical activity and pharmacotherapy. Meanwhile, the trial group subdivided into Baduanjin group and other exercises group according to their own situations, COPD Assessment Test (CAT), the modified Medical Research Council (mMRC) Dyspnea Scale, number of acute exacerbation and spirometry were analyzed before, 6 months post and 12 months post. Results: After 12 months of annular management, CAT score of patients in the management group decreased 3.76, mMRC scale decreased 0.45, the number of acute exacerbation less than twice increased to 75%, which were superior to those of the control group ([Formula: see text]). Decreasing score of CAT and mMRC scale in Baduanjin group were much more than that in other exercise subgroup ([Formula: see text]). Conclusion: “Tertiary hospitals–Community Health Service Institutions–Family health care workers/patients to participate in the annular management of COPD” model can alleviate the symptoms of patients with stable COPD, improve the life quality and reduce the risk of exacerbation, and is more integrated than medication management. Baduanjin as Chinese characteristic pulmonary rehabilitation exercise is worthy of further promotion due to better outstanding other than sports in improving the quality of life.
{"title":"Evaluation of the curative effect of “Tertiary hospitals–Community Health Service Institutions–Family health care workers/Patients to participate in the annular management of COPD” model in the treatment of chronic obstructive pulmonary disease","authors":"Cuiling Feng, Yufeng Meng, Jian-hui Wang, Zhiyun Yang, Wei Zhou, Yun-sheng Gao, Xiaoqin Yao, Guang-jun Xue, Xiaotian Liu, Lei Li, Linyang Wang, Chengxiang Wang, Fengsen Li","doi":"10.1142/S257590001850009X","DOIUrl":"https://doi.org/10.1142/S257590001850009X","url":null,"abstract":"Objective: To evaluate the curative effect of “Tertiary hospitals–Community Health Service Institutions–Family health care workers/patients to participate in the annular management of COPD” model in the treatment of chronic obstructive pulmonary disease (COPD). Methods: 516 patients with COPD in the stable period of the disease were invited to participate in this cluster randomized trial with 260 patients in the trial group, and the other 256 in the control group. All the patients were treated with the routine medicine regimen. The integrated intervention for the trial group includes educational activity, physical activity and pharmacotherapy. Meanwhile, the trial group subdivided into Baduanjin group and other exercises group according to their own situations, COPD Assessment Test (CAT), the modified Medical Research Council (mMRC) Dyspnea Scale, number of acute exacerbation and spirometry were analyzed before, 6 months post and 12 months post. Results: After 12 months of annular management, CAT score of patients in the management group decreased 3.76, mMRC scale decreased 0.45, the number of acute exacerbation less than twice increased to 75%, which were superior to those of the control group ([Formula: see text]). Decreasing score of CAT and mMRC scale in Baduanjin group were much more than that in other exercise subgroup ([Formula: see text]). Conclusion: “Tertiary hospitals–Community Health Service Institutions–Family health care workers/patients to participate in the annular management of COPD” model can alleviate the symptoms of patients with stable COPD, improve the life quality and reduce the risk of exacerbation, and is more integrated than medication management. Baduanjin as Chinese characteristic pulmonary rehabilitation exercise is worthy of further promotion due to better outstanding other than sports in improving the quality of life.","PeriodicalId":23184,"journal":{"name":"Traditional Medicine and Modern Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S257590001850009X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46559956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1142/S2575900018200021
Juan Chen, L. Qi, Chen Zhao, Xiehong Shi, Tao Yi
The paper analyzes China's top designs including the “One Belt and One Road” (B&R) Initiative and the B&R Development Plan of TCM, and discusses measures of actors including governmental institutions, academic groups, medical institutions, and research institutes. Survey to foreigners in Shanghai on acupuncture and moxibustion of traditional Chinese medicine (TCM) reflects the recognition level, advantages and disadvantages, and overseas spread of Chinese Acu-moxi internationally. Based on the above as well as comprehensive inspection on various factors, the paper provides several suggestions to Chinese Acu-moxi development under the background of the B&R Initiative.
{"title":"Development and prospects of acupuncture and moxibustion of TCM under the “One Belt & One Road” Initiative — Based on survey of foreigners' cognition on Acu-moxi in Shanghai","authors":"Juan Chen, L. Qi, Chen Zhao, Xiehong Shi, Tao Yi","doi":"10.1142/S2575900018200021","DOIUrl":"https://doi.org/10.1142/S2575900018200021","url":null,"abstract":"The paper analyzes China's top designs including the “One Belt and One Road” (B&R) Initiative and the B&R Development Plan of TCM, and discusses measures of actors including governmental institutions, academic groups, medical institutions, and research institutes. Survey to foreigners in Shanghai on acupuncture and moxibustion of traditional Chinese medicine (TCM) reflects the recognition level, advantages and disadvantages, and overseas spread of Chinese Acu-moxi internationally. Based on the above as well as comprehensive inspection on various factors, the paper provides several suggestions to Chinese Acu-moxi development under the background of the B&R Initiative.","PeriodicalId":23184,"journal":{"name":"Traditional Medicine and Modern Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S2575900018200021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42633928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1142/S2575900018400025
Wen-Qiang Cui, Wen Sun, Q. Mao-Ying, W. Mi, Yu-Xia Chu, Yan-Qing Wang
Objective: This study aims to systematically evaluate the efficacy and safety of catgut implantation at acupoints (CIA) treating asthma, extracting data from the published clinical trials. Methods: The Cochrane Library, PubMed, Chinese Biomedical Database (CBM), CNKI, WANFANG and VIP databases were searched up to February 2017. Randomized controlled trials (RCTs) involving CIA or CIA plus conventional medicine treatment (CMT) were selected with CMT as control. We assessed the methodological quality of RCTs using the Cochrane Handbook for Systematic Review of Interventions. The outcome data of trials were analyzed using RevMan5.3. Results: A total of 12 studies ([Formula: see text]) were included. Most of the included studies were assessed to have high risk of bias with low quality of methodology. CIA application significantly improved the overall therapeutic efficacy ([Formula: see text]) and pulmonary function (forced expiratory volume in 1[Formula: see text]s (FEV1) and FEV1%, [Formula: see text] and [Formula: see text]) and reduced the overall scores of TCM symptoms ([Formula: see text]). Further, it significantly relieved several TCM symptoms including shortness of breath, chest distress and cough ([Formula: see text]). However, CIA only exerted a protective tendency for expectoration and wheezing without significant difference and had no effects on recurrence rate (all [Formula: see text]). Conclusions: CIA treatment could improve the overall efficacy and pulmonary function and relief several symptoms. However, the evidence remains weak. Rigorous and larger trials will be the basis of the effectiveness and long-term effects of CIA therapies.
{"title":"Evaluation of catgut implantation at acupoints for asthma: A systematic review and meta-analysis","authors":"Wen-Qiang Cui, Wen Sun, Q. Mao-Ying, W. Mi, Yu-Xia Chu, Yan-Qing Wang","doi":"10.1142/S2575900018400025","DOIUrl":"https://doi.org/10.1142/S2575900018400025","url":null,"abstract":"Objective: This study aims to systematically evaluate the efficacy and safety of catgut implantation at acupoints (CIA) treating asthma, extracting data from the published clinical trials. Methods: The Cochrane Library, PubMed, Chinese Biomedical Database (CBM), CNKI, WANFANG and VIP databases were searched up to February 2017. Randomized controlled trials (RCTs) involving CIA or CIA plus conventional medicine treatment (CMT) were selected with CMT as control. We assessed the methodological quality of RCTs using the Cochrane Handbook for Systematic Review of Interventions. The outcome data of trials were analyzed using RevMan5.3. Results: A total of 12 studies ([Formula: see text]) were included. Most of the included studies were assessed to have high risk of bias with low quality of methodology. CIA application significantly improved the overall therapeutic efficacy ([Formula: see text]) and pulmonary function (forced expiratory volume in 1[Formula: see text]s (FEV1) and FEV1%, [Formula: see text] and [Formula: see text]) and reduced the overall scores of TCM symptoms ([Formula: see text]). Further, it significantly relieved several TCM symptoms including shortness of breath, chest distress and cough ([Formula: see text]). However, CIA only exerted a protective tendency for expectoration and wheezing without significant difference and had no effects on recurrence rate (all [Formula: see text]). Conclusions: CIA treatment could improve the overall efficacy and pulmonary function and relief several symptoms. However, the evidence remains weak. Rigorous and larger trials will be the basis of the effectiveness and long-term effects of CIA therapies.","PeriodicalId":23184,"journal":{"name":"Traditional Medicine and Modern Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S2575900018400025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47483897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1142/S2575900018500088
Fei Xu, Wen-Qiang Cui, Ying Wei, Jingcheng Dong, Baojun Liu
Background: Serum markers, such as Krebs von den Lungen-6 (KL-6), are reported to reflect the severity, progression and prognosis of idiopathic pulmonary fibrosis (IPF). We aimed to evaluate whether tumor markers could improve the diagnosis of connective tissue diseases (CTDs) and predict CTD-related interstitial lung diseases (ILDs) (CTD–ILD); and whether there was a significant difference between ILD patients with CTD and without CTD (non-CTD–ILD). Methods: In this study, 146 patients with ILD only, 61 with CTD–ILD, 102 with lung cancer (LC), 111 with COPD, and 46 with CTD were enrolled. Serum levels of several tumor markers were collected. Results: Compared with COPD, the serum levels of CEA, NSE, CYFRA21-1, CA19-9 and CA125 were higher, but the level of SCC was lower; meanwhile, there were significant differences in NSE, SCC, CYFRA21-1 and CA125 between CTD–ILD and non-CTD–ILD groups. Conclusions: It appears that tumor-associated antigens may be the predictive factors for CTD–ILD that could be used to identify CTD from ILD before it is detected on autoimmune symptoms or auto-antibodies. However, further studies are needed to validate our findings and determine whether serum tumor markers have prognostic value or predict progressive CTD–ILD.
背景：据报道，血清标志物，如Krebs-von den Lungen-6（KL-6），可反映特发性肺纤维化（IPF）的严重程度、进展和预后。我们旨在评估肿瘤标志物是否可以改善结缔组织疾病（CTDs）的诊断，并预测CTD相关的间质性肺病（ILDs）（CTD–ILD）；以及患有CTD和未患有CTD的ILD患者之间是否存在显著差异（非CTD–ILD）。方法：本研究纳入146例单纯ILD患者、61例CTD-ILD患者，102例肺癌（LC）患者、111例COPD患者和46例CTD患者。采集了几种肿瘤标志物的血清水平。结果：与COPD相比，血清CEA、NSE、CYFRA21-1、CA19-9和CA125水平较高，而SCC水平较低；同时，CTD–ILD组和非CTD–ILD组的NSE、SCC、CYFRA21-1和CA125存在显著差异。结论：肿瘤相关抗原可能是CTD–ILD的预测因素，可用于在自身免疫症状或自身抗体上检测到CTD之前从ILD中识别CTD。然而，还需要进一步的研究来验证我们的发现，并确定血清肿瘤标志物是否具有预后价值或预测进行性CTD–ILD。
{"title":"Association of serum tumor markers with interstitial lung disease in patients with or without connective tissue disease: A cross-sectional study","authors":"Fei Xu, Wen-Qiang Cui, Ying Wei, Jingcheng Dong, Baojun Liu","doi":"10.1142/S2575900018500088","DOIUrl":"https://doi.org/10.1142/S2575900018500088","url":null,"abstract":"Background: Serum markers, such as Krebs von den Lungen-6 (KL-6), are reported to reflect the severity, progression and prognosis of idiopathic pulmonary fibrosis (IPF). We aimed to evaluate whether tumor markers could improve the diagnosis of connective tissue diseases (CTDs) and predict CTD-related interstitial lung diseases (ILDs) (CTD–ILD); and whether there was a significant difference between ILD patients with CTD and without CTD (non-CTD–ILD). Methods: In this study, 146 patients with ILD only, 61 with CTD–ILD, 102 with lung cancer (LC), 111 with COPD, and 46 with CTD were enrolled. Serum levels of several tumor markers were collected. Results: Compared with COPD, the serum levels of CEA, NSE, CYFRA21-1, CA19-9 and CA125 were higher, but the level of SCC was lower; meanwhile, there were significant differences in NSE, SCC, CYFRA21-1 and CA125 between CTD–ILD and non-CTD–ILD groups. Conclusions: It appears that tumor-associated antigens may be the predictive factors for CTD–ILD that could be used to identify CTD from ILD before it is detected on autoimmune symptoms or auto-antibodies. However, further studies are needed to validate our findings and determine whether serum tumor markers have prognostic value or predict progressive CTD–ILD.","PeriodicalId":23184,"journal":{"name":"Traditional Medicine and Modern Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S2575900018500088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44813038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1142/S2575900018300023
Jing Lin, Tianjiao Lv, Fubo Tian, Yan Wang, Ming-yan Wang, W. Tang, H. Gober, Xuemin Qiu, Dajin Li, Ling Wang
Whether Chinese herbal formulas are effective in treatment of postmenopausal osteoporosis remains unclear. The aim of this study is to explore the experimental evidence of both in vitro and in vivo preclinical studies using Chinese herbal formulas in postmenopausal osteoporosis. Searches were applied to various databases with relevant keywords. Original in vivo and in vitro studies using Chinese herbal formulas to treat postmenopausal osteoporosis, and with full text available, were included. Er-Xian Decoction, Bu-Shen-Ning-Xin Decoction, Qing E Formula, Liuwei Dihuang Wan, and Xian-Ling-Gu-Bao Decoction, the most commonly studied formulas, were selected from the pool of Chinese medicine. The preclinical data indicated the potential use of Chinese herbal formulas in postmenopausal osteoporosis. The underlying mechanisms included bone morphogenetic protein (BMP), Wnt/[Formula: see text]-catenin, extracellular-signal-regulated kinase/c-Jun [Formula: see text] terminal kinase/mitogen-activated protein kinase (ERK/JNK/MAPK), estrogen receptor (ER), and osteoprotegerin/receptor activator of nuclear factor [Formula: see text]B ligand (OPG/RANKL) signaling pathways. This study demonstrated the anti-osteoporotic effect of Chinese herbal formulas targeting different pathways in bone metabolism. Further study with adequate sample size and follow-up time, appropriate controls, and optimal blinding is required.
{"title":"Chinese herbal formulas for postmenopausal osteoporosis: A review of preclinical evidence on animal studies and molecular mechanism","authors":"Jing Lin, Tianjiao Lv, Fubo Tian, Yan Wang, Ming-yan Wang, W. Tang, H. Gober, Xuemin Qiu, Dajin Li, Ling Wang","doi":"10.1142/S2575900018300023","DOIUrl":"https://doi.org/10.1142/S2575900018300023","url":null,"abstract":"Whether Chinese herbal formulas are effective in treatment of postmenopausal osteoporosis remains unclear. The aim of this study is to explore the experimental evidence of both in vitro and in vivo preclinical studies using Chinese herbal formulas in postmenopausal osteoporosis. Searches were applied to various databases with relevant keywords. Original in vivo and in vitro studies using Chinese herbal formulas to treat postmenopausal osteoporosis, and with full text available, were included. Er-Xian Decoction, Bu-Shen-Ning-Xin Decoction, Qing E Formula, Liuwei Dihuang Wan, and Xian-Ling-Gu-Bao Decoction, the most commonly studied formulas, were selected from the pool of Chinese medicine. The preclinical data indicated the potential use of Chinese herbal formulas in postmenopausal osteoporosis. The underlying mechanisms included bone morphogenetic protein (BMP), Wnt/[Formula: see text]-catenin, extracellular-signal-regulated kinase/c-Jun [Formula: see text] terminal kinase/mitogen-activated protein kinase (ERK/JNK/MAPK), estrogen receptor (ER), and osteoprotegerin/receptor activator of nuclear factor [Formula: see text]B ligand (OPG/RANKL) signaling pathways. This study demonstrated the anti-osteoporotic effect of Chinese herbal formulas targeting different pathways in bone metabolism. Further study with adequate sample size and follow-up time, appropriate controls, and optimal blinding is required.","PeriodicalId":23184,"journal":{"name":"Traditional Medicine and Modern Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S2575900018300023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42883661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：